Germany-based Medigene has announced an update and prioritization of its pipeline and resource allocation in support of its long-term corporate strategy. 22 November 2023
InDex Pharmaceuticals Pharmaceuticals plunged 60% to 0.26 kronor this morning, as it reported a failed clinical trial for its ulcerative colitis candidate cobitolimod. 22 November 2023
Just six months after raising $150 million in an upsized series E financing, cardiometabolic specialist Carmot Therapeutics has filed for an initial public offering (IPO). 21 November 2023
Shares of US pharma major Bristol Myers Squibb fell more than 4% pre-market and partner 2seventy bio was down 17.6% at $1.76 on Monday, after the companies said the US Food and Drug Administration would miss its target date for potential approval of earlier use of a cancer therapy Abecma (idecabtagene vicleucel). 21 November 2023
A reverse merger will see two Massachusetts, USA-based companies, Q32 Bio and Homology Medicines, joining forces to focus on the former’s autoimmune and inflammatory disease candidates. 20 November 2023
China-based CStone Pharmaceuticals’ Cejemly (sugemalimab) has been approved by the China National Medical Products Administration (NMPA) for the treatment of relapsed or refractory extranodal natural killer/T-cell lymphoma (r/r ENKTL). 20 November 2023
Utah, USA-based biotech Halia Therapeutics has appointed Lisa Shamon as vice president of regulatory affairs and Xianne Penny as a senior medical director. 17 November 2023
The European Commission (EC) has granted marketing authorization for China-headquartered biotech BeiGene’s Brukinsa (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma. 17 November 2023
Boston, USA-based biotechnology start-up PostEra, which specializes in artificial intelligence for pre-clinical drug discovery, has entered into a multi-target collaboration with US biotech major Amgen. 17 November 2023
US drug developer SpringWorks Therapeutics today announced what it described as positive top-line results from its Phase IIb ReNeu trial evaluating mirdametinib. 16 November 2023
A new cell therapy company has launched in Cambridge, UK, with $59 million in series A funding provided by Sofinnova Partners and others, including Sanofi Ventures. 16 November 2023
Adding to the collaboration agreed last December, Gilead Sciences’ subsidiary Kite has today announced it is expanding it collaboration with US biotech Arcellx. 15 November 2023
Antibody specialist Nona Biosciences has entered into a strategic collaboration with Chinese bioconjugation company GeneQuantum Healthcare. 15 November 2023
Markets have reacted warmly to a radical plan from Theseus Pharmaceuticals to cut costs and potentially put itself up for a sale or merger. 15 November 2023
London-listed blood disease specialist Hemogenyx Pharmaceuticals has announced the successful completion of the re-manufacturing of an improved lentivirus (LVV) devoid of splice variants. 15 November 2023
Swiss drugmaker Basilea Pharmaceutica has entered into an asset purchase agreement with Amplyx Pharmaceuticals to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. 14 November 2023
Autifony Therapeutics, an independent biotech company formed in 2011 as a spin-out from GSK, has announced a collaboration with Ireland-headquartered Jazz Pharmaceuticals. 14 November 2023
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024